Search Results

Press Releases

Novaliq and Laboratoires Théa Announce Partnership and EU Approval for Vevizye® (Ciclosporin 0.1% Eye Drops Solution)

October 2, 2024

·

5 min read

Policy

European Medicines Agency Accepts Novaliq’s Marketing Authorization Application for CyclASol® (ciclosporin ophthalmic solution) 0.1% for the Treatment of Dry Eye Disease

Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, announced that the European Medicines Agency has accepted the marketing authorization application for CyclASol for regulatory review.

August 24, 2023

·

3 min read

Deals

Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq

Harrow (Nasdaq: HROW) and Novaliq GmbH today announced an agreement under which Harrow will acquire the U.S. and Canadian commercial rights for VEVYE® (cyclosporine ophthalmic solution) 0.1%, a patented, non‑preserved, ophthalmic solution prescription drug based on Novaliq’s proprietary EyeSol® water-free technology.

July 18, 2023

·

11 min read

FDA

Novaliq Announces FDA Approval of VEVYE™ (Cyclosporine Ophthalmic Solution) 0.1% for the Treatment of the Signs and Symptoms of Dry Eye Disease

Novaliq GmbH today announced that the U.S. Food and Drug Administration (FDA) has approved VEVYE™ (cyclosporine ophthalmic solution) 0.1% for the treatment of the signs and symptoms of dry eye disease.

June 8, 2023

·

5 min read

Press Releases

Niterra Ventures Company Invests $18M Additional Funding in Neoplas Med GmbH

November 25, 2024

·

4 min read

Business

Senju Pharmaceutical and Novaliq Enter Into License Agreement For NOV03 (Perfluorohexyloctane Ophthalmic Solution) For the Treatment of Dry Eye Disease in Japan

Senju Pharmaceutical Co., Ltd. and Novaliq GmbH are pleased to announce the closing of a license agreement on Japan rights to develop, manufacture, and commercialize NOV03, the first and only prescription treatment for signs and symptoms of dry eye disease that directly targets tear evaporation.

June 13, 2023

·

5 min read

Genetown

CORRECTING and REPLACING Senju Pharmaceutical and Novaliq Enter Into License Agreement For NOV03 (Perfluorohexyloctane Ophthalmic Solution) For the Treatment of Dry Eye Disease in Japan

Senju Pharmaceutical Co., Ltd. and Novaliq GmbH are pleased to announce the closing of a license agreement on Japan rights to develop, manufacture, and commercialize NOV03, the first and only prescription treatment for signs and symptoms of dry eye disease that directly targets tear evaporation.

June 13, 2023

·

5 min read

Deals

Great Point Partners Acquires Lyocontract GmbH, Germany-Based Drug Product CDMO

Great Point Partners, a Greenwich-based investment firm focused exclusively on the health care industry, announced the acquisition of Lyocontract GmbH, a premium independent drug product contract development and manufacturing organization based in Ilsenburg, Germany.

June 13, 2024

·

3 min read

Business

Oakwood Chemical Announces Strategic Partnership with EMP Biotech GmbH

Oakwood Chemical is thrilled to unveil its collaboration with EMP Biotech GmbH, a move set to streamline the oligo synthesis supply chain.

April 9, 2024

·

2 min read

FDA

Bausch + Lomb and Novaliq Announce FDA Approval of MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”)and Novaliq GmbH today announced that the U.S. Food and Drug Administration (FDA) has approved MIEBO™ (perfluorohexyloctane ophthalmic solution; formerly known as NOV03), for the treatment of the signs and symptoms of dry eye disease (DED).

May 18, 2023

·

9 min read